Kidney Cancer xx (20xx) x-xx 6 Mini-Abstract. 7 We report our one-year experience on the use of Tivozanib in metastatic Renal Cell Carcinoma (RCC) in n=23 patients treated within a year after approval. Tumor response according to RECIST criteria was PR in 39.1%, SD in 52.2% and PD in 8.7% of the patients. Median progression free survival (PFS) was 14.9 months (95% CI 5.1-24.8).
of all-line therapies, we could see a progression free 43 survival of 14.9 months, exceeding the pivotal data. 44 How might it impact clinical practice in the 45 foreseeable future? 46 The field of kidney cancer is rapidly changing, as immune-modulating drugs such as, nivolumab, ipil- We present our clinical experience one year after 103 the drug was available in Europe. comparable to the pivotal trial and therefore proof that 247 the use of tivozanib is safe and oncological beneficial.
248
Nonetheless our data have to be interpreted with 249 caution, given the small sample size and short follow- 
